Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma

Yael Kusne, Eugenio A. Carrera-Silva, Anthony S. Perry, Elisabeth J. Rushing, Edward K. Mandell, Justin D. Dietrich, Andrea E. Errasti, Daniel Gibbs, Michael E. Berens, Joseph C. Loftus, Christopher Hulme, Weiwei Yang, Zhimin Lu, Kenneth Aldape, Nader Sanai, Carla V. Rothlin, Sourav Ghosh

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Grade IV glioblastoma is characterized by increased kinase activity of epidermal growth factor receptor (EGFR); however, EGFR kinase inhibitors have failed to improve survival in individuals with this cancer because resistance to these drugs often develops. We showed that tumor necrosis factor-α (TNFα) produced in the glioblastoma microenvironment activated atypical protein kinase C (aPKC), thereby producing resistance to EGFR kinase inhibitors. Additionally, we identified that aPKC was required both for paracrine TNFα-dependent activation of the transcription factor nuclear factor κB (NF-κB) and for tumor cell-intrinsic receptor tyrosine kinase signaling. Targeting aPKC decreased tumor growth in mouse models of glioblastoma, including models of EGFR kinase inhibitor-resistant glioblastoma. Furthermore, aPKC abundance and activity were increased in human glioblastoma tumor cells, and high aPKC abundance correlated with poor prognosis. Thus, targeting aPKC might provide an improved molecular approach for glioblastoma therapy.

Original languageEnglish (US)
Article numberra75
JournalScience Signaling
Volume7
Issue number338
DOIs
StatePublished - Aug 12 2014

Fingerprint

Glioblastoma
Epidermal Growth Factor Receptor
Tumor Necrosis Factor-alpha
Cytokines
Tumors
Neoplasms
Cells
Receptor Protein-Tyrosine Kinases
Drug Resistance
PKC-3 protein
Transcription Factors
Phosphotransferases
Chemical activation
Survival
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Kusne, Y., Carrera-Silva, E. A., Perry, A. S., Rushing, E. J., Mandell, E. K., Dietrich, J. D., ... Ghosh, S. (2014). Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma. Science Signaling, 7(338), [ra75]. https://doi.org/10.1126/scisignal.2005196

Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma. / Kusne, Yael; Carrera-Silva, Eugenio A.; Perry, Anthony S.; Rushing, Elisabeth J.; Mandell, Edward K.; Dietrich, Justin D.; Errasti, Andrea E.; Gibbs, Daniel; Berens, Michael E.; Loftus, Joseph C.; Hulme, Christopher; Yang, Weiwei; Lu, Zhimin; Aldape, Kenneth; Sanai, Nader; Rothlin, Carla V.; Ghosh, Sourav.

In: Science Signaling, Vol. 7, No. 338, ra75, 12.08.2014.

Research output: Contribution to journalArticle

Kusne, Y, Carrera-Silva, EA, Perry, AS, Rushing, EJ, Mandell, EK, Dietrich, JD, Errasti, AE, Gibbs, D, Berens, ME, Loftus, JC, Hulme, C, Yang, W, Lu, Z, Aldape, K, Sanai, N, Rothlin, CV & Ghosh, S 2014, 'Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma', Science Signaling, vol. 7, no. 338, ra75. https://doi.org/10.1126/scisignal.2005196
Kusne, Yael ; Carrera-Silva, Eugenio A. ; Perry, Anthony S. ; Rushing, Elisabeth J. ; Mandell, Edward K. ; Dietrich, Justin D. ; Errasti, Andrea E. ; Gibbs, Daniel ; Berens, Michael E. ; Loftus, Joseph C. ; Hulme, Christopher ; Yang, Weiwei ; Lu, Zhimin ; Aldape, Kenneth ; Sanai, Nader ; Rothlin, Carla V. ; Ghosh, Sourav. / Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma. In: Science Signaling. 2014 ; Vol. 7, No. 338.
@article{49b20a5c328b4a75b08abb7cd51f01f8,
title = "Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma",
abstract = "Grade IV glioblastoma is characterized by increased kinase activity of epidermal growth factor receptor (EGFR); however, EGFR kinase inhibitors have failed to improve survival in individuals with this cancer because resistance to these drugs often develops. We showed that tumor necrosis factor-α (TNFα) produced in the glioblastoma microenvironment activated atypical protein kinase C (aPKC), thereby producing resistance to EGFR kinase inhibitors. Additionally, we identified that aPKC was required both for paracrine TNFα-dependent activation of the transcription factor nuclear factor κB (NF-κB) and for tumor cell-intrinsic receptor tyrosine kinase signaling. Targeting aPKC decreased tumor growth in mouse models of glioblastoma, including models of EGFR kinase inhibitor-resistant glioblastoma. Furthermore, aPKC abundance and activity were increased in human glioblastoma tumor cells, and high aPKC abundance correlated with poor prognosis. Thus, targeting aPKC might provide an improved molecular approach for glioblastoma therapy.",
author = "Yael Kusne and Carrera-Silva, {Eugenio A.} and Perry, {Anthony S.} and Rushing, {Elisabeth J.} and Mandell, {Edward K.} and Dietrich, {Justin D.} and Errasti, {Andrea E.} and Daniel Gibbs and Berens, {Michael E.} and Loftus, {Joseph C.} and Christopher Hulme and Weiwei Yang and Zhimin Lu and Kenneth Aldape and Nader Sanai and Rothlin, {Carla V.} and Sourav Ghosh",
year = "2014",
month = "8",
day = "12",
doi = "10.1126/scisignal.2005196",
language = "English (US)",
volume = "7",
journal = "Science Signaling",
issn = "1937-9145",
publisher = "American Association for the Advancement of Science",
number = "338",

}

TY - JOUR

T1 - Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma

AU - Kusne, Yael

AU - Carrera-Silva, Eugenio A.

AU - Perry, Anthony S.

AU - Rushing, Elisabeth J.

AU - Mandell, Edward K.

AU - Dietrich, Justin D.

AU - Errasti, Andrea E.

AU - Gibbs, Daniel

AU - Berens, Michael E.

AU - Loftus, Joseph C.

AU - Hulme, Christopher

AU - Yang, Weiwei

AU - Lu, Zhimin

AU - Aldape, Kenneth

AU - Sanai, Nader

AU - Rothlin, Carla V.

AU - Ghosh, Sourav

PY - 2014/8/12

Y1 - 2014/8/12

N2 - Grade IV glioblastoma is characterized by increased kinase activity of epidermal growth factor receptor (EGFR); however, EGFR kinase inhibitors have failed to improve survival in individuals with this cancer because resistance to these drugs often develops. We showed that tumor necrosis factor-α (TNFα) produced in the glioblastoma microenvironment activated atypical protein kinase C (aPKC), thereby producing resistance to EGFR kinase inhibitors. Additionally, we identified that aPKC was required both for paracrine TNFα-dependent activation of the transcription factor nuclear factor κB (NF-κB) and for tumor cell-intrinsic receptor tyrosine kinase signaling. Targeting aPKC decreased tumor growth in mouse models of glioblastoma, including models of EGFR kinase inhibitor-resistant glioblastoma. Furthermore, aPKC abundance and activity were increased in human glioblastoma tumor cells, and high aPKC abundance correlated with poor prognosis. Thus, targeting aPKC might provide an improved molecular approach for glioblastoma therapy.

AB - Grade IV glioblastoma is characterized by increased kinase activity of epidermal growth factor receptor (EGFR); however, EGFR kinase inhibitors have failed to improve survival in individuals with this cancer because resistance to these drugs often develops. We showed that tumor necrosis factor-α (TNFα) produced in the glioblastoma microenvironment activated atypical protein kinase C (aPKC), thereby producing resistance to EGFR kinase inhibitors. Additionally, we identified that aPKC was required both for paracrine TNFα-dependent activation of the transcription factor nuclear factor κB (NF-κB) and for tumor cell-intrinsic receptor tyrosine kinase signaling. Targeting aPKC decreased tumor growth in mouse models of glioblastoma, including models of EGFR kinase inhibitor-resistant glioblastoma. Furthermore, aPKC abundance and activity were increased in human glioblastoma tumor cells, and high aPKC abundance correlated with poor prognosis. Thus, targeting aPKC might provide an improved molecular approach for glioblastoma therapy.

UR - http://www.scopus.com/inward/record.url?scp=84906094991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906094991&partnerID=8YFLogxK

U2 - 10.1126/scisignal.2005196

DO - 10.1126/scisignal.2005196

M3 - Article

C2 - 25118327

AN - SCOPUS:84906094991

VL - 7

JO - Science Signaling

JF - Science Signaling

SN - 1937-9145

IS - 338

M1 - ra75

ER -